Page 14 - Flipbook

Commentary

• Potential to be practice changing

• DFS positive and OS pending but there is a signal

• This will likely lead to FDA approval but will other countries

need to wait for OS before reimbursement?

• If no OS: pembro now vs pembro later

• If positive OS: pembro will be standard of care

• M1 NED data interesting: is using IO earlier better?

• Will other PD(L)1 therapies work?

• Is there quality of life data?

• What about perioperative strategies like nivolumab?

• Better or worse?